智通财经APP讯,百利天恒(688506.SH)公告,公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药SI-B036双特异性抗体注射液的药物临床试验获得批准,同意该品单药在晚期实体瘤中开展临床试验。
据悉,SI-B036双特异性抗体注射液是公司自主研发的全球领先的特异性增强双特异性抗体平台(SEBA平台)的产品之一,SEBA分子不仅可以提高靶向性和抗肿瘤活性,还可以最大限度地减少脱靶效应。
智通财经APP讯,百利天恒(688506.SH)公告,公司近日收到国家药品监督管理局(NMPA)正式批准签发的《药物临床试验批准通知书》,公司自主研发的创新生物药SI-B036双特异性抗体注射液的药物临床试验获得批准,同意该品单药在晚期实体瘤中开展临床试验。
据悉,SI-B036双特异性抗体注射液是公司自主研发的全球领先的特异性增强双特异性抗体平台(SEBA平台)的产品之一,SEBA分子不仅可以提高靶向性和抗肿瘤活性,还可以最大限度地减少脱靶效应。
Disclaimer: Investing carries risk. This is not financial advice. The above content should not be regarded as an offer, recommendation, or solicitation on acquiring or disposing of any financial products, any associated discussions, comments, or posts by author or other users should not be considered as such either. It is solely for general information purpose only, which does not consider your own investment objectives, financial situations or needs. TTM assumes no responsibility or warranty for the accuracy and completeness of the information, investors should do their own research and may seek professional advice before investing.